Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal Ranibizumab
Access status:
Open Access
Type
ArticleAuthor/s
Bell, Katy J.L.Hayen, Andrew
Glasziou, Paul
Mitchell, Andrew S
Farris, Maria
Wright, Jonathan
Duerr, Hans-Peter
Mitchell, Paul
Irwig, Les
Abstract
Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.
See less
See less
Date
2017Source title
RETINA, The Journal of Retinal and Vitreous DiseasesVolume
37Issue
3Publisher
Lippincott, Williams & WilkinsLicence
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0Faculty/School
Faculty of Medicine and Health, Sydney School of Public HealthShare